Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than ...

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

The tumor necrosis factor (TNF)–TNF receptor families of proteins are known to mediate both inflammation and apoptosis. One of the receptor members of this family, CD95 or Fas, is believed to play a ...

New York, USA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | ...

Peptide conjugation techniques are advancing CNS delivery of oligonucleotides, addressing blood-brain barrier challenges and ...

The use of oligonucleotides as therapeutic agents is of great interest, particularly when it comes to siRNA and antisense oligonucleotides. However, the difficulty of targeting the right organ and ...

A new addition to a series of articles that focus on important topics related to the development of oligonucleotide therapeutics presents an in-depth look at the identification, characterization, and ...

Oligonucleotide therapeutics make up a small but rapidly growing segment of the overall global drug pipeline, with 245 programs currently in development today. While only one approved oligo ...

Creyon Bio, an oligonucleotide research specialist with the goal of designing precision medicines, has emerged with $40 million from a series A financing round led by DCVC Bio and Lux Capital. Creyon ...

Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market by Product ((Drugs (ASO, SiRNA), Synthesized Oligos (Product (Primers, Probes)), Type ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent ...

GSK has added another oligonucleotide to its pipeline, with potentially plenty more to follow courtesy of a $170 million upfront collaboration with Wave Life Sciences. As part of the deal, GSK will ...